Paper36045346
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
Garces de Los Fayos Alonso I and 39 others. Mol Cancer, 2022. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma. Papers, record 36045346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36045346
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymphoma, Large-Cell, Anaplastic | Major topic |
| Receptor, Platelet-Derived Growth Factor beta | Major topic |
| STAT3 Transcription Factor | Major topic |
| STAT5 Transcription Factor | Major topic |
| Anaplastic Lymphoma Kinase | |
| Animals | |
| Carcinogenesis | |
| Cell Line, Tumor | |
| Humans | |
| Mice | |
| Phosphorylation | |
| Signal Transduction |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| I 4066 | Austrian Science Fund FWF | Austria | PubMed | PubMed | |
| I 4156 | Austrian Science Fund FWF | Austria | PubMed | PubMed | |
| I 4154 | Austrian Science Fund FWF | Austria | PubMed | PubMed | |
| P 27132 | Austrian Science Fund FWF | Austria | PubMed | PubMed | |
| R35 CA210064 | NCI NIH HHS | United States | R35CA210064 | PubMed | NIH RePORTER |
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11090048 | CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. | Blood | 2000 | https://conductscience.org/library/papers/11090048 | PubMed |
| 2 | 34320169 | A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. | Blood | 2021 | https://conductscience.org/library/papers/34320169 | PubMed |
| 3 | 15659500 | Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15659500 | PubMed |
| 4 | 15827959 | Human IL-19 regulates immunity through auto-induction of IL-19 and production of IL-10. | Eur J Immunol | 2005 | https://conductscience.org/library/papers/15827959 | PubMed |
| 5 | 29728695 | Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. | Leukemia | 2018 | https://conductscience.org/library/papers/29728695 | PubMed |
| 6 | 31366041 | The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31366041 | PubMed |
| 7 | 17922009 | STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. | Nat Med | 2007 | https://conductscience.org/library/papers/17922009 | PubMed |
| 8 | 9777954 | Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. | Am J Pathol | 1998 | https://conductscience.org/library/papers/9777954 | PubMed |
| 9 | 33310759 | Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis. | Life Sci Alliance | 2021 | https://conductscience.org/library/papers/33310759 | PubMed |
| 10 | 18232729 | Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model. | PLoS Med | 2008 | https://conductscience.org/library/papers/18232729 | PubMed |
| 11 | 31690038 | STAT5A and STAT5B-Twins with Different Personalities in Hematopoiesis and Leukemia. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31690038 | PubMed |
| 12 | 22187331 | Dynamic CpG-DNA methylation of Il10 and Il19 in CD4+ T lymphocytes and macrophages: effects on tissue-specific gene expression. | Klin Padiatr | 2012 | https://conductscience.org/library/papers/22187331 | PubMed |
| 13 | 26736010 | Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26736010 | PubMed |
| 14 | 19088198 | Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/19088198 | PubMed |
| 15 | 31817106 | JAK2 Inhibition Impairs Proliferation and Sensitises Cervical Cancer Cells to Cisplatin-Induced Cell Death. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31817106 | PubMed |
| 16 | 30679796 | Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. | Leukemia | 2019 | https://conductscience.org/library/papers/30679796 | PubMed |
| 17 | 31756496 | Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. | J Thorac Oncol | 2020 | https://conductscience.org/library/papers/31756496 | PubMed |
| 18 | 29284669 | MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29284669 | PubMed |
| 19 | 33352844 | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/33352844 | PubMed |
| 20 | 17908974 | Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17908974 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42881166 | Ablation of CDK6 and STAT5B rewires T cell developmental dynamics and prevents ALK+ lymphoma formation. | Nat Commun | 2026 | https://conductscience.org/library/papers/42881166 | PubMed |
| 41924268 | IQDMA disrupts STAT5 nuclear transport through CDC42-PAK2 axis collapse in cutaneous T-cell lymphoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/41924268 | PubMed |
| 41107802 | Novel combination therapy with phenformin enhances the effects of lenvatinib in hepatocellular carcinoma via AMPK-mediated PDGFRβ degradation. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41107802 | PubMed |
| 40591076 | Mechanistic study of butylphthalide in alleviating cerebral Edema after intracerebral Hemorrhage by regulating miR-7-5p expression. | Metab Brain Dis | 2025 | https://conductscience.org/library/papers/40591076 | PubMed |
| 40376194 | JAK-STAT Signaling in Autoimmunity and Cancer. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/40376194 | PubMed |
| 40364836 | Role of FHOD1 in tumor cells and tumor immune microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/40364836 | PubMed |
| 40175628 | HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy. | Leukemia | 2025 | https://conductscience.org/library/papers/40175628 | PubMed |
| 40073758 | Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome. | Redox Biol | 2025 | https://conductscience.org/library/papers/40073758 | PubMed |
| 40055571 | ALK in cancer: from function to therapeutic targeting. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/40055571 | PubMed |
| 38745318 | PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility. | J Exp Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38745318 | PubMed |
| 38618957 | Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia. | J Clin Invest | 2024 | https://conductscience.org/library/papers/38618957 | PubMed |
| 38306597 | Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs). | Blood | 2024 | https://conductscience.org/library/papers/38306597 | PubMed |
| 38172648 | The regulatory relationship between transcription factor STAT3 and noncoding RNA. | Cell Mol Biol Lett | 2024 | https://conductscience.org/library/papers/38172648 | PubMed |
| 37608819 | Dental Pulp Stem Cell-Derived Exosomes Regulate Anti-Inflammatory and Osteogenesis in Periodontal Ligament Stem Cells and Promote the Repair of Experimental Periodontitis in Rats. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/37608819 | PubMed |
| 37564202 | A novel mouse model of heart failure with preserved ejection fraction after chronic kidney disease induced by retinol through JAK/STAT pathway. | Int J Biol Sci | 2023 | https://conductscience.org/library/papers/37564202 | PubMed |
| 37173951 | The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37173951 | PubMed |
Genes35
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36045346
GET https://conductscience.org/api/papers/v1/36045346/authors?page=2